Investing Profile

Felice Verduyn - van Weegen

VCInvestor

Partner at EQT Group

eqtgroup.com/about/people/fel...Amsterdam, Netherlands

Your Intro Paths to Felice Verduyn - van Weegen

Signal uses Gmail to reveal intro paths. Email content is never read.

Networks Felice is a member of

Hotmail Network

4983 CONNECTIONS

Mckinsey & Company Network

635 CONNECTIONS

Columbia University - Columbia Business School Network

268 CONNECTIONS

Harvard Medical School Network

67 CONNECTIONS

VU University Amsterdam Network

42 CONNECTIONS

Find Felice Verduyn - van Weegen on

Current Investing Position

EQT Group Partner

Investment Range

$11.0M - $65.0M

Sweet Spot

$25.0M

Investments On Record

Felice Verduyn - van Weegen is on these Sector & Stage Rankings

BioTech (Series B)Health & Hospital Services (Series B)Health IT (Series A)BioTech (Series A)Health & Hospital Services (Series A)Digital Health (Series B)Health IT (Series B)Digital Health (Series A)

Felice Verduyn - van Weegen's Investments On Record (6)

Company	StageDateRound Size	Total Raised
Noema Pharma	Series BDec 2024$150M	$260M
Co-investors: Nanna Luneborg (Forbion), Antoine Papiernik Papiernik (Sofinnova Partners)
Vico Therapeutics	Series BJan 2024$72M Series AJul 2020$31M	$120M
Co-investors: Amy Schulman (Polaris Partners), Jean-François Rivassou (Kurma Partners), Martijn Kleijwegt (Life Sciences Partners), Silvia Noiman (Pontifax Venture Capital), Rémi Droller (Financial Services, Financial Technology, and Business Services)
AgomAb Therapeutics	Series COct 2023$100M	$200M
Co-investors: Colleen Cuffaro (Canaan Partners), Ohad Hammer (Pontifax Venture Capital), Iyona Rajkomar (Dawn Biopharma)
Amolyt Pharma	Series CJan 2023$140M Series BSep 2021$80M	$290M
Co-investors: Ohad Hammer (Pontifax Venture Capital), Thierry Laugel (Kurma Partners), Iyona Rajkomar (Dawn Biopharma), Raphael Wisniewski (Andera Partners)
Egle Therapeutics	Series AOct 2021$47M	$47M
Co-investors: Vincent Brichard (EQT Group), Jacques Mizrahi (Bioqube Ventures)
AM Pharma	Series FJul 2019$130M	$210M
Co-investors: Joël Jean-Mairet (Ysios Capital), Laia Crespo (Sanofi Ventures), Rémi Droller (Financial Services, Financial Technology, and Business Services), Martijn Kleijwegt (Life Sciences Partners), Raphael Wisniewski (Andera Partners), Geert-Jan Mulder (Forbion)

Felice Verduyn - van Weegen's Experience

Genetic and Twin Research Amsterdam Sustainability Institute - VU AmsterdamPresent

Genetic and Twin Research HotmailPresent

Genetic research fellow Harvard Medical SchoolPresent

Fellow Mckinsey & CompanyPresent

Investment Manager LSPPresent

Board Observer ONWARD MedicalPresent

Board Observer PharvarisPresent

Member Board Of Directors Amolyt PharmaPresent

Chairman of the supervisory board De ZorgambassadePresent

Member of the Supervisory Board Vico TherapeuticsPresent

Member Board Of Directors EvommunePresent

Member Board Of Directors Egle TherapeuticsPresent

Member Board of Directors AgomabPresent

Member Board of Directors Noema PharmaPresent

Chairman of Grant Committee EQT FoundationPresent

Partner LSPPresent

Partner EQT GroupPresent

Felice Verduyn - van Weegen's Education

VU University Amsterdam Bachelor's degree Biological Psychology

Vrije Universiteit Amsterdam (VU Amsterdam) Bachelor's degree Biological Psychology

VU University Amsterdam MsC Neurosciences

Vrije Universiteit Amsterdam (VU Amsterdam) MsC Neurosciences

Erasmus Universiteit Rotterdam MsC Neurosciences

Erasmus University Rotterdam MsC Neurosciences

Columbia University - Columbia Business School Master of Business Administration (MBA) with honors

Investors who invest with Felice Verduyn - van Weegen

Scouts & Angels Affiliated With Felice Verduyn - van Weegen